Celularity vs uniQure
CELU and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and QURE compare
uniQure is the larger company, worth 78 times as much as Celularity ($1.4B against $18.5M).
uniQure grew revenue faster over the last twelve months (30.2% versus −58.1% for Celularity).
Celularity keeps more of each dollar of sales as profit, with a net margin of −246% compared with −1351% at uniQure.
Celularity scores higher on the StockData Score (7 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | QURE |
|---|---|---|
| Size and price | ||
| Market cap | $18.5M | $1.4B |
| Share price | $0.571 | $20.78 |
| Change, 1 year | −63.2% | −30.5% |
| Change, 5 years | −99.2% | −27.9% |
| Beta (5Y) | 1.89 | 3.14 |
| Employees | 115 | 221 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 77.2× |
| P/B | – | 4.4× |
| FCF yield | – | −11.2% |
| Fair value | – | $6.42 |
| Margin of safety | – | −224% |
| Growth | ||
| Revenue growth (TTM) | −58.1% | 30.2% (better) |
| Revenue growth, 5Y average | 13.2% (better) | −15.6% |
| Profitability | ||
| Gross margin | 19.2% | 92.5% (better) |
| Operating margin | −264% (better) | −1072% |
| Net margin | −246% (better) | −1351% |
| FCF margin | – | −865% |
| Return on equity | – | −158% |
| Financial health | ||
| Debt / equity | – | 0.15 |
| Interest coverage | – | −3.4× |
| Current ratio | 0.11 | 10.01 (better) |
| Altman Z-score | −16.49 | −0.51 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 96.0% |
| Held by insiders | – | 2.1% |
| Insider net buying, 12 months | – | −$20.2M |
| Short interest, % of float | – | 12.5% |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- QURE stock overview
- QURE income statement
- QURE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.